https://www.selleckchem.com/pr....oducts/avotaciclib-t
001) and +1.0 mmHg (P = 0.007) with GLIM. More patients achieved HbA1c less then 7.0% (53 mmol/mol) (44.3% vs. 34.3%; P = 0.044), and fewer patients required treatment intensification (1.3% vs. 8.8%; P = 0.002) with DAPA + SAXA than with GLIM. CONCLUSIONS Compared with GLIM, concurrent addition of DAPA + SAXA significantly improved glycaemic control, body weight and other metabolic parameters in patients inadequately controlled on metformin. Trial NCT02419612, ClinicalTrials.gov. © 2020 The Authors. Diabetes, Obesit
Like
Comment
Share
